Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis
To the Editor:
Although most research on cystic fibrosis (CF) disease pathogenesis has focused on epithelia (1), recent work shows that CF transmembrane conductance regulator (CFTR) is expressed on human and murine monocytes and macrophages (2, 3) and that CFTR deficiency could alter these cells' functions (2, 4, 5) . Although these findings raise the possibility that immune dysfunction contributes to CF disease pathogenesis, questions remain. First, although some studies identified defects in CF monocytes and macrophages (2, 5, 6) , other studies have not (7) . Second, abnormalities in human cells could be a primary consequence of CFTR dysfunction or secondary effects caused by the disease environment. Third, although studies in mice may be less affected by secondary disease manifestations, they may be complicated by species differences. Finally, prior studies have investigated specific myeloid cell functions and may have missed unsuspected consequences of CFTR dysfunction.
We exploited an opportunity to investigate how CFTR channel activity affects monocyte functioning by studying peripheral blood monocytes from patients starting therapy with the CFTR potentiator ivacaftor. Ivacaftor increases CFTR-G551D channel opening and improves sweat chloride and lung function ( Figures 1A and 1B) (8) . We measured the plasma membrane (PM)-associated proteome (9) of monocytes from 12 patients with CFTR-G551D mutations (Table 1) before and 2 and 7 days after treatment with ivacaftor. We focused on the PM-associated proteome because these proteins mediate immune functions, serve as biomarkers, and may suggest disease mechanisms (9) . The study design reduced variability because each patient served as his/her own control, and studying monocytes ( Figure 1C ) avoided in vitro culture to produce macrophages and ensured that drug exposure occurred in vivo.
As our primary goal was to better understand whether CFTR dysfunction affects monocyte functions, we wished to identify proteins altered as a direct consequence of restored CFTR activity. We reasoned that proteins that changed rapidly after ivacaftor initiation were likely candidates, as late changes may be more affected by secondary effects. However, because ivacaftor requires 3-5 days to reach steady-state levels (10), studying very early time points could miss emergent changes. We addressed this problem by first identifying proteins that changed significantly at Day 7 and then testing this group of proteins for changes at Day 2, using Gene Set Enrichment Analysis (GSEA) (11) . GSEA determines whether a priori-defined proteins (i.e., proteins changed at Day 7) show significant and concordant changes at a point where effects may be more modest (i.e., Day 2).
Using stringent statistical criteria that combined the t and G tests (false discovery rate, ,0.05), we identified 21 PM-associated proteins whose abundance significantly changed at Day 7 ( Figure 1D and see Table E1 in the online supplement). Importantly, GSEA found that many proteins that changed significantly at Day 7 showed a similar regulatory pattern, but smaller-magnitude changes, at Day 2 (P = 0.02-0.0007; Figures 1E and E1 ).
We used gene ontology analysis to determine whether ivacaftor affected particular functional pathways and found that ivacaftor disproportionately increased proteins associated with cell migration (P = 10
25
; Figure 1F ). Ivacaftor increased ENO1 and PFN1, which enhance monocyte migration across epithelia and endothelia, and ICAM3 and CORO1A, which participate in leukocyte migration. This is notable because CFTR has not previously been linked to cell migration.
Gene ontology analysis also revealed that ivacaftor disproportionately reduced monocyte proteins involved in inflammation, including S100A9, MX1, and HLA-B (P = 10 24 ; Figure 1F ). S100A9 is a biomarker of CF inflammation (12) , HLA-B mediates antigen presentation, and MX1 mediates antiviral responses.
Remarkably, all of the inflammation-related proteins reduced by ivacaftor are IFNg induced. IFNg can also arrest monocyte chemotaxis (13) . Thus, both the decreases in inflammation-related proteins and the increases in monocyte-migration proteins we observed could be linked to dampened IFNg responses.
The simplest mechanism to explain decreased IFNg responses in monocytes would be that ivacaftor decreased circulating IFNg levels. We thus measured plasma IFNg levels and found them unchanged ( Figure 1G ). These findings led us to hypothesize that CF monocytes may have increased sensitivity to ambient IFN and that ivacaftor decreases sensitivity. This hypothesis predicts that ivacaftor will decrease the levels of PM-associated STAT1, as STAT1 is recruited to the PM during IFNg signaling (14) . As shown in Figure 1F , ivacaftor markedly decreased PM-associated STAT1. Together, these results suggest that CF monocytes may have increased IFNg sensitivity, and that increased sensitivity may be mediated by increased STAT1 activation. However, IFNg responses can also be regulated by STAT1-independent mechanisms, and additional confirmatory work is needed.
One mechanism by which CFTR dysfunction could increase monocyte IFNg sensitivity and increase STAT1 PM recruitment is decreased IFNg receptor endocytosis (14) . Previous work indicates that CF macrophages have decreased LPS receptor endocytosis, and as a consequence, have exaggerated LPS responses (4). Thus, defective receptor endocytosis in CF myeloid cells could be a common mechanism that produces both increased LPS and IFNg sensitivity.
A key question for future research is whether dampened IFNg sensitivity is a direct effect of ivacaftor on monocyte CFTR channel activity or a secondary effect of decreased systemic inflammation (see model, Figure 1J ). Our study cannot distinguish between these possibilities. Arguing for a direct effect, we found no ivacaftormediated decrease in blood leukocyte counts, IFNg levels, or C-reactive protein (12) (Figures 1G-1I) . Also arguing for a direct effect, GSEA found that many proteins significantly changed at Day 7 showed concordant changes at Day 2 ( Figures 1E and E1 ). Arguing against a direct effect, lung function is known to increase 3 days after ivacaftor treatment (8) . Thus, it is possible that the proteomic changes are secondary to ivacaftor-mediated improvements in general health.
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